Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA.
Info & Links
CEO
David P. Meeker
Headquarters
222 BERKELEY STREET, 12TH FLOOR BOSTON, MA 02116, UNITED STATES
Rhythm Pharmaceuticals, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
5.76B
Enterprise Value
5.70B
Enterprise Value/EBITDA(ttm)
-29.92
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
30.76
Price to Book(mrq)
41.02
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
89.58%
Operating Margin(ttm)
-103.57%
Profit Margin(ttm)
-111.36%
Return on Equity(ttm)
-266.56%
Return on Invested Capital(ttm)
-100.74%
Return on Assets(ttm)
-45.01%
Income Statement
Revenue(ttm)
189.76M
Revenue Per Share(ttm)
2.78
Gross Profit(ttm)
170.26M
EBITDA(ttm)3
-190.68M
Net Income Available to Common(ttm)
-201.92M
Diluted EPS(ttm)
-3.11
Share Statistics
Beta (5Y Monthly)
2.14
52-Week Change
40.01%
S&P 500 52-Week Change
27.10%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
68.29M
Dividend Yield
0.00%
Float4
64.12M
% Held by Insiders
6.10%
% Held by Institutions
--
Balance Sheet
Total Cash(mrq)
388.95M
Total Cash Per Share(mrq)
5.70
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
4.41%
Quick Ratio(mrq)
4.16%
Book Value Per Share(mrq)
4.02
Cash Flow
Operating Cash Flow Per Share(ytd)
-1.78
Free Cash Flow(ytd)
-156.63M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.